Cargando…

1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients

BACKGROUND: Pediatric hematopoietic cell transplant recipients (PHCTRs) have poor serologic responses to influenza vaccination. While absolute numbers of circulating B and T cells are important predictors of response, our goal was to identify B and T cell subpopulations associated with vaccine immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Amarin, Justin Z, Simmons, Joshua, Hayek, Haya, Dulek, Daniel, Spieker, Andrew J, Chappell, James, Halasa, Natasha B, Kalams, Spyros A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678083/
http://dx.doi.org/10.1093/ofid/ofad500.073
_version_ 1785150281622749184
author Amarin, Justin Z
Simmons, Joshua
Hayek, Haya
Dulek, Daniel
Spieker, Andrew J
Chappell, James
Halasa, Natasha B
Kalams, Spyros A
author_facet Amarin, Justin Z
Simmons, Joshua
Hayek, Haya
Dulek, Daniel
Spieker, Andrew J
Chappell, James
Halasa, Natasha B
Kalams, Spyros A
author_sort Amarin, Justin Z
collection PubMed
description BACKGROUND: Pediatric hematopoietic cell transplant recipients (PHCTRs) have poor serologic responses to influenza vaccination. While absolute numbers of circulating B and T cells are important predictors of response, our goal was to identify B and T cell subpopulations associated with vaccine immunogenicity. METHODS: We conducted a secondary analysis of PHCTRs enrolled in a multicenter randomized controlled influenza vaccine trial spanning three influenza seasons (2016–2019). Peripheral blood mononuclear cells were collected before vaccination and 28–42 days after the second dose, and they were analyzed using mass cytometry (CyTOF). We fit linear regression models to estimate relationships between strain-specific (A/H3N2, A/H1N1, and B/Victoria) pre- to post-vaccination (28–42 days) serum hemagglutination-inhibition antibody titers vs. log-transformed cell counts, including vaccine dose as a covariate. We used the Benjamini–Yekutieli method to adjust for multiplicity. We conducted a subsequent sensitivity analysis, including time from transplant as an additional covariate, for cell populations identified as predictive of response to all three antigens. RESULTS: We included 156 PHCTRs. The median age at first vaccination was 11.8 years (IQR, 6.8–14.3 years), and the median time from transplantation was 7.9 months (IQR, 4.3–13.6 months). High-dose trivalent or standard-dose quadrivalent inactivated influenza vaccine was administered to 79 (50.6%) and 77 (49.4%) PHCTRs, respectively. Mass cytometry revealed 33 distinct cell subpopulations, seven of which were significant predictors of geometric mean titer ratio for all three antigens after two vaccine doses, irrespective of dose (Table 1). We found evidence that subpopulations 1 and 18 (related B cell subpopulations differing by BTLA and CCR6 expression), 8 (CD8+ naïve T cells), and 19 (CD4+ T follicular helper cells) predicted titers irrespective of dose and time from transplantation. Table 1 [Figure: see text] Figure 1 [Figure: see text] UMAP from a 32-parameter CyTOF antibody panel generated from 156 PHCTRs at the time of vaccination. Major islands of CD4+ T cells, CD8+ T cells, and B cells are demarcated. Figure 2 [Figure: see text] Heat map of cell subpopulations identified by CyTOF. The frequency of several cell subpopulations predicted subsequent serological responses to multiple vaccine immunogens, including 1 and 18 (B cells), 5 and 7 (naïve CD4+ T cells), 19 (memory cTfh cells), and 23 (CD8+ memory T cells). CONCLUSION: We identified distinct B and T cell subpopulations predictive of influenza vaccine immunogenicity in PHCTRs. Our findings may improve the identification of PHCTRs at high-risk for influenza due to impaired influenza vaccine immunogenicity and aid in the development of effective vaccine strategies in this population. DISCLOSURES: Daniel Dulek, MD, Eurofins Viracor: Research supplies Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support
format Online
Article
Text
id pubmed-10678083
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106780832023-11-27 1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients Amarin, Justin Z Simmons, Joshua Hayek, Haya Dulek, Daniel Spieker, Andrew J Chappell, James Halasa, Natasha B Kalams, Spyros A Open Forum Infect Dis Abstract BACKGROUND: Pediatric hematopoietic cell transplant recipients (PHCTRs) have poor serologic responses to influenza vaccination. While absolute numbers of circulating B and T cells are important predictors of response, our goal was to identify B and T cell subpopulations associated with vaccine immunogenicity. METHODS: We conducted a secondary analysis of PHCTRs enrolled in a multicenter randomized controlled influenza vaccine trial spanning three influenza seasons (2016–2019). Peripheral blood mononuclear cells were collected before vaccination and 28–42 days after the second dose, and they were analyzed using mass cytometry (CyTOF). We fit linear regression models to estimate relationships between strain-specific (A/H3N2, A/H1N1, and B/Victoria) pre- to post-vaccination (28–42 days) serum hemagglutination-inhibition antibody titers vs. log-transformed cell counts, including vaccine dose as a covariate. We used the Benjamini–Yekutieli method to adjust for multiplicity. We conducted a subsequent sensitivity analysis, including time from transplant as an additional covariate, for cell populations identified as predictive of response to all three antigens. RESULTS: We included 156 PHCTRs. The median age at first vaccination was 11.8 years (IQR, 6.8–14.3 years), and the median time from transplantation was 7.9 months (IQR, 4.3–13.6 months). High-dose trivalent or standard-dose quadrivalent inactivated influenza vaccine was administered to 79 (50.6%) and 77 (49.4%) PHCTRs, respectively. Mass cytometry revealed 33 distinct cell subpopulations, seven of which were significant predictors of geometric mean titer ratio for all three antigens after two vaccine doses, irrespective of dose (Table 1). We found evidence that subpopulations 1 and 18 (related B cell subpopulations differing by BTLA and CCR6 expression), 8 (CD8+ naïve T cells), and 19 (CD4+ T follicular helper cells) predicted titers irrespective of dose and time from transplantation. Table 1 [Figure: see text] Figure 1 [Figure: see text] UMAP from a 32-parameter CyTOF antibody panel generated from 156 PHCTRs at the time of vaccination. Major islands of CD4+ T cells, CD8+ T cells, and B cells are demarcated. Figure 2 [Figure: see text] Heat map of cell subpopulations identified by CyTOF. The frequency of several cell subpopulations predicted subsequent serological responses to multiple vaccine immunogens, including 1 and 18 (B cells), 5 and 7 (naïve CD4+ T cells), 19 (memory cTfh cells), and 23 (CD8+ memory T cells). CONCLUSION: We identified distinct B and T cell subpopulations predictive of influenza vaccine immunogenicity in PHCTRs. Our findings may improve the identification of PHCTRs at high-risk for influenza due to impaired influenza vaccine immunogenicity and aid in the development of effective vaccine strategies in this population. DISCLOSURES: Daniel Dulek, MD, Eurofins Viracor: Research supplies Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support Oxford University Press 2023-11-27 /pmc/articles/PMC10678083/ http://dx.doi.org/10.1093/ofid/ofad500.073 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Amarin, Justin Z
Simmons, Joshua
Hayek, Haya
Dulek, Daniel
Spieker, Andrew J
Chappell, James
Halasa, Natasha B
Kalams, Spyros A
1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
title 1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
title_full 1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
title_fullStr 1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
title_full_unstemmed 1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
title_short 1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
title_sort 1100. cellular immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678083/
http://dx.doi.org/10.1093/ofid/ofad500.073
work_keys_str_mv AT amarinjustinz 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients
AT simmonsjoshua 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients
AT hayekhaya 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients
AT dulekdaniel 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients
AT spiekerandrewj 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients
AT chappelljames 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients
AT halasanatashab 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients
AT kalamsspyrosa 1100cellularimmunophenotypicpredictorsofinfluenzavaccineimmunogenicityinpediatrichematopoieticcelltransplantrecipients